Pluristem Therapeutics

Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory and hematologic conditions. The firm focuses on the development, clinical trials and manufacturing of cell therapeutics and related technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. The firm focuses on the research, development, and manufacturing of cell-based products and technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

HAIFA, Israel, April  30, 2020  (GLOBE NEWSWIRE) -- ﻿

EIB signs collaboration with Israel Innovation Authority and €50 million financing agreement with Pluristem to develop therapies for COVID-19 and other unmet medical needs

Athersys

Mesoblast

Promising results from a very small study caused shares of stem cell stocks to soar, but investors shouldn't get too carried away just yet.

Are Stem Cells the COVID-19 Treatment We've All Been Waiting For?

The stem cell developer found a financing solution that won't dilute shareholders. Well, not immediately, anyway.

Here's Why Pluristem Therapeutics Jumped Over 28% Today

EXPECTED ONLINE SIGNING CEREMONY ON APRIL 30, 2020 EXPECTED ONLINE SIGNING CEREMONY ON APRIL 30, 2020

Pluristem Secures €50 Million Non-Dilutive Financing from the European Investment Bank to Support its COVID-19 Project and Phase III Studies

Orgenesis

Teladoc

Orgenesis Acquiring Tamir, And Other News: The Good, Bad And Ugly Of Biopharma

Pluristem (PSTI) gains on the treatment of first patient suffering from COVID-19 complications with its cell therapy.

Pluristem Up on Cell Therapy Treatment of Coronavirus Patient

Gilead Sciences

Johnson & Johnson

Pfizer

Regeneron Pharmaceuticals

With the coronavirus outbreak gaining steam worldwide, pharma/biotech companies are evaluating every possible therapy to combat the spread.

Will Stem Cell Therapies Aid in Fight Against Coronavirus?

HAIFA, Israel, April  13, 2020  (GLOBE NEWSWIRE) --  Pluristem Therapeutics Inc.   (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today that it has treated its first patient suffering from COVID-19 complications in the United States under the U.S. Food and Drug Administration’s (FDA) Single Patient Expanded Access Program, also called a compassionate use program, which is part of the U.S. Coronavirus Treatment Acceleration Program (CTAP), an emergency program for possible therapies that uses every available method to move new treatments to patients as quickly as possible.

Pluristem Expands its Compassionate Use Program: Treated First COVID-19 Patient in U.S. Under FDA Single Patient Expanded Access Program

Investors need to pay close attention to Pluristem (PSTI) stock based on the movements in the options market lately.

Implied Volatility Surging for Pluristem (PSTI) Stock Options

Pluristem Therapeutics (NASDAQ: PSTI) shares are trading higher on Tuesday, after the company reported preliminary data from its coronavirus compassionate use program, treating seven patients with acute respiratory failure.

Why Pluristem Therapeutics Trading Higher Today

HAIFA, Israel, April  07, 2020  (GLOBE NEWSWIRE) --   Pluristem Therapeutics Inc.    (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today preliminary data from its compassionate use program, treating seven patients suffering from acute respiratory failure and inflammatory complications associated with COVID-19 with Pluristem’s PLX cells, in three medical centers in Israel.  

Pluristem Reports Preliminary Data from its COVID-19 Compassionate Use Program, Treating Seven Patients with Acute Respiratory Failure

HAIFA, Israel, March  30, 2020  (GLOBE NEWSWIRE) --   Pluristem Therapeutics Inc.    (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological therapeutic products, announced today that since its  last update on COVID-19 , it has dosed three patients in two different hospitals in Israel under a compassionate use program for the treatment of COVID-19, as approved by the Israeli Ministry of Health. Pluristem expects to enroll additional patients in Israel in the coming days and anticipates providing updates on clinical outcomes once significant data has been gathered.

Pluristem Treated First Three COVID-19 Patients in Israel under Compassionate Use

HAIFA, Israel, March  26, 2020  (GLOBE NEWSWIRE) --  Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products, today issued an update to its shareholders from its Chief Executive Officer and President, Yaky Yanay.

Pluristem Provides Update on COVID-19:  Preparedness, Current Phase III Clinical Trials Status and Treatment Development Activity

HAIFA, Israel, March  12, 2020  (GLOBE NEWSWIRE) -- HAIFA, Israel,  March 12, 20 20  -    Pluristem Therapeutics Inc.    (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products, today announced it has signed a collaborative agreement with the BIH Center for Regenerative Therapy (BCRT) and the Berlin Center for Advanced Therapies (BeCAT) at Charite’ University of Medicine Berlin to expand its existing framework and research agreement and conduct a joint project evaluating the therapeutic effects of Pluristem’s patented PLX cell product candidates for potential treatment of the respiratory and inflammatory complications associated with the COVID-19 coronavirus.

Pluristem and Charité University of Medicine Berlin Join Forces Targeting Potential Treatment for Respiratory and Inflammatory Intratissue Complications Caused by COVID-19

HAIFA, Israel, Feb.  10, 2020  (GLOBE NEWSWIRE) --   Pluristem Therapeutics Inc.    (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel cell therapy products, today issued an update to its shareholders from its Chief Executive Officer and President, Yaky Yanay.

Pluristem Therapeutics CEO Issues Shareholder Update

HAIFA, Israel, Feb.  03, 2020  (GLOBE NEWSWIRE) --   Pluristem Therapeutics Inc.    (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing a platform of novel biological products, today announced results from a market access comprehensive research study conducted by Marwood Group, a healthcare advisory firm, for the critical limb ischemia (CLI) market in the U.S. The report included data from published literature as well as direct interviews regarding Pluristem’s PLX-PAD regenerative cell therapy with dozens of physicians, who are key opinion leaders (KOL) in CLI, and with payers covering millions of lives. Pluristem believes that the in-depth report reflects a favorable market for PLX-PAD, which is currently in a global Phase III study with clinical sites in the U.S., Europe, and Israel. According to the report, CLI is a significant unmet need indication, and constitutes a significant burden on the U.S. healthcare system. The report suggests that the addressable market for PLX-PAD for Rutherford 5 CLI patients that are unsuitable for revascularization is expected to reach $2 billion by 2023. In addition, the physicians interviewed as part of the study suggest that they would use the PLX product in cases where multiple medical interventions are needed per year. Based on the report, and assuming such an approach, this could support an annual addressable market in the U.S. of $6 billion.

In Its Path Towards Marketing, Pluristem Provides Highly Favorable Market Access Data Regarding the Critical Limb Ischemia Market in U.S.

Patients unsuitable for revascularization surgery currently have no alternative treatments, leading to high risk of leg amputation and death; PLX-PAD may become the first drug approved to treat CLI Patients unsuitable for revascularization surgery currently have no alternative treatments, leading to high risk of leg amputation and death; PLX-PAD may become the first drug approved to treat CLI

Pluristem Completes 75% Enrollment in its Pivotal Phase III CLI Clinical Study

As of late, it has definitely been a great time to be an investor Pluristem Therapeutics.

Pluristem Therapeutics Shares March Higher, Can It Continue?

Multinational study in the U.S., Israel and Europe targeting to be the first product candidate supporting muscle regeneration after significant trauma such as hip fracture Multinational study in the U.S., Israel and Europe targeting to be the first product candidate supporting muscle regeneration after significant trauma such as hip fracture

Pluristem Reaches Milestone in its Phase III Muscle Injury Study, Completes 50% Enrollment

HAIFA, Israel, Nov.  12, 2019  (GLOBE NEWSWIRE) --  Pluristem Therapeutics Inc.  (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today issued an update to its shareholders from its Chief Executive Officer, Yaky Yanay.

Pluristem Therapeutics CEO Issues  Shareholder Update

Pluristem Therapeutics has been struggling lately, but the selling pressure may be coming to an end soon.

Pluristem Therapeutics Sees Hammer Chart Pattern: Time to Buy?

HAIFA, Israel, Sept.  16, 2019  (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc . (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today provided a recap of the  Key Opinion Leader call  hosted by the company this morning to review unmet medical needs in acute radiation syndrome (ARS) and hematological deficiencies, and to provide an update on the development of its novel cell therapy treatment, PLX-R18. PLX cell therapy was granted an Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of ARS and incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT).

Pluristem Therapeutics Recaps Key Opinion Leader Call Reviewing Hematological Programs

Data readout from second cohort of hematological study will be presented Call scheduled for Monday, September 16 at 10:00am ET Data readout from second cohort of hematological study will be presented Call scheduled for Monday, September 16 at 10:00am ET

Pluristem Therapeutics to Host Key Opinion Leader Call on Its Acute Radiation Syndrome and Hematological Programs

HAIFA, Israel, Aug.  21, 2019  (GLOBE NEWSWIRE) --  Pluristem Therapeutics Inc.  (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that the company will host a live Key Opinion Leader (KOL) call on its hematological programs on September 16, 2019.

News for Pluristem Therapeutics Stock (PSTI)